Covalent Biologic Drugs: A Faster, Safer Way to Target Disease
Official title: CHEMICAL PLATFORM FOR COVALENT BIOLOGICS
Funded at University of Houston · NIH-11433403 · Data updated 2026-11-12
A new platform aims to create fast-acting biologic drugs that stick to targets quickly and clear from the body to treat diseases like rheumatoid arthritis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $1,399,908 |
| NIH project number | 1R01GM166176-01 |
| Project ID | NIH-11433403 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include people with inflammatory conditions like rheumatoid arthritis who could benefit from improved biologic therapies.
✕Less likely to help
Patients with conditions not driven by the intended targets or those unable to participate in animal studies may not benefit.
What this research studies
This project proposes a streamlined platform to make covalent biologics, which are small enough to reach tissues rapidly but still bind strongly to disease targets. It uses SuFEx chemistry to enable quick covalent bonding and tests covalent-reversible designs to reduce side effects. The work includes evaluating cellular effects and testing the drugs in mouse models of rheumatoid arthritis to gauge real-world potential. If successful, it could provide a versatile method to develop next-generation biologics with better potency and safety.
Why it matters
Potential benefit: If successful, patients could gain faster-acting biologic therapies with improved targeting and potentially fewer side effects.
How similar studies have gone: Past covalent biologic approaches have shown promise, but this platform aims to provide a broadly applicable, faster, and safer method.
Where this research is happening
-
University of Houston
Houston, United States Active
Researchers
- Principal investigator: Statsyuk, Alexander V — University of Houston
- Study coordinator: Statsyuk, Alexander V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.